NantKwest: Multiple Presentations at Immunotherapy of Cancer Conference

Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials

NantKwest (NASDAQ: NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be making multiple presentations associated with the company’s off-the-shelf CD16 targeted NK cell (hanK) and NANT Cancer Vaccine platform at the upcoming Society for Immunotherapy of Cancer (SITC) Conference which runs from November 7 – 11 in Washington D.C.

SITC Conference Details:

Title:				First in human data in advanced solid tumors of NANT Cancer Vaccine: A novel temporospatial orchestration of the innate (NK) & adaptive immune system to induce antigen cascade & immunogenic cell death
Session:				Immune Escape: Currently Understanding of Mechanisms and Advances in Therapeutics Approaches
Date/Time:				Wednesday, November 7, 2018, 5:45pm EST
Type:				Oral Presentation
Title:				NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater metastatic pancreatic cancer
Date:				Friday, November 9, 2018
Type:				Poster Presentation/Abstract #P713
Location:				Hall E
Title:				NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater TNBC and head & neck cancer
Date:				Saturday, November 10, 2018
Type:				Poster Presentation/Abstract #P310
Location:				Hall E

https://www.biospace.com/article/releases/nantkwest-announces-multiple-presentations-at-the-2018-society-for-immunotherapy-of-cancer-conference/